SAN DIEGO--(BUSINESS WIRE)--FibroGen, Inc. today announced results of a phase 1b study of FG-3019, a fully human monoclonal antibody against connective tissue growth factor (CTGF), in people with type 1 or type 2 diabetes and microalbuminuria (the earliest clinical sign of diabetic nephropathy). The data (Abstract TH-PO239) were presented at Renal Week 2006, the annual meeting of the American Society of Nephrology (ASN), by Sharon G. Adler, MD, Associate Chief, Division of Nephrology and Hypertension, Harvard UCLA Medical Center, and Professor of Medicine, UCLA School of Medicine.
